A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Case Rep
Hlavní autoři: Yamaoka, Keiko, Nagashima, Shuichi, Okada, Nobukazu, Sawayama, Nagisa, Saito, Shinsuke, Takahashi, Manabu, Okada, Kenta, Endo, Kazuhiro, Koizumi, Masaru, Sasanuma, Hideki, Ebihara, Ken, Kasajima, Atsuko, Fukushima, Noriyoshi, Sata, Naohiro, Ishibashi, Shun
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Case Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8133073/
https://ncbi.nlm.nih.gov/pubmed/34026158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.4118
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky